{"doc_id": "esur__v00000000", "chunk_id": "000000", "text": "# ESUR", "section": "ESUR", "page_from": null, "page_to": null, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "43b96be243395069b340505c364318d5f766c0961d602dbb145cd6daf1b9b30b"}
{"doc_id": "esur__v00000000", "chunk_id": "000001", "text": "Rizzo et al. European Radiology (2025) 35:4029–4039\nhttps://doi.org/10.1007/s00330-024-11300-7\nS P E C I A L RE P O R T\nOp e n A c c e ss\nOvarian cancer staging and follow-up:\nupdated guidelines from the European\nSociety of Urogenital Radiology female\npelvic imaging working group\nStefania Rizzo1,2, Giacomo Avesani3*\n, Camilla Panico3, Lucia Manganaro4, Benedetta Gui3, Yulia Lakhman5,\nPamela Causa Andrieu6, Nishat Bharwani7, Andrea Rockall8, Isabelle Thomassin-Naggara9,\nTeresa Margarida Cunha10, Evis Sala3, Rosemarie Forstner11 and Stephanie Nougaret12\nAbstract\nObjective To provide up-to-date European Society of Urogenital Radiology (ESUR) guidelines for staging and follow-\nup of patients with ovarian cancer (OC).\nMethods Twenty-one experts, members of the female pelvis imaging ESUR subcommittee from 19 institutions,\nreplied to 2 rounds of questionnaires regarding imaging techniques and structured reporting used for pre-treatment\nevaluation of OC patients. The results of the survey were presented to the other authors during the group’s annual\nmeeting. The lexicon was aligned with the Society of American Radiology (SAR)-ESUR lexicon; a ﬁrst draft was", "section": "S P E C I A L RE P O R T", "page_from": 1, "page_to": 1, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "4aa2ebfdb0e7a557c365b45898fe7daf68f988515860346a8403b278aa23e787"}
{"doc_id": "esur__v00000000", "chunk_id": "000002", "text": "meeting. The lexicon was aligned with the Society of American Radiology (SAR)-ESUR lexicon; a ﬁrst draft was\ncirculated, and then comments and suggestions from the other authors were incorporated.\nResults Evaluation of disease extent at diagnosis should be performed by chest, abdominal, and pelvic CT. The\nradiological report should map the disease with speciﬁc mention of sites that may preclude optimal cytoreductive\nsurgery. For suspected recurrence, CT and [18F]FDG PET-CT are both valid options. MRI can be considered in\nexperienced centres, as an alternative to CT, considering the high costs and the need for higher expertise in reporting.\nConclusions CT is the imaging modality of choice for preoperative evaluation and follow-up in OC patients. A\nstructured radiological report, including speciﬁc mention of sites that may preclude optimal debulking, is of value for\npatient management.\nKey Points\nQuestion Guidelines were last published for ovarian cancer (OC) imaging in 2010; here, guidance on imaging techniques\nand reporting, incorporating advances in the ﬁeld, are provided.", "section": "S P E C I A L RE P O R T", "page_from": 1, "page_to": 1, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "b8104ca674740bf6ba04390563037ffb8044cd706b89b69921b7d29e78cd98e6"}
{"doc_id": "esur__v00000000", "chunk_id": "000003", "text": "Key Points\nQuestion Guidelines were last published for ovarian cancer (OC) imaging in 2010; here, guidance on imaging techniques\nand reporting, incorporating advances in the ﬁeld, are provided.\nFindings Structured reports should map out sites of disease, highlighting sites that limit cytoreduction. For suspected\nrecurrence, CT and 18FDG PET-CT are options, and MRI can be considered.\nClinical relevance Imaging evaluation of OC patients at initial diagnosis (mainly based on CT), using a structured report\nthat considers surgical needs is valuable in treatment selection and planning.\n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use,\nsharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s)\nand the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material\nin this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not", "section": "S P E C I A L RE P O R T", "page_from": 1, "page_to": 1, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "c7b2c8e6abdd51f8c015eaf9c70bdf328fab95ffad3aa21fb84a506e0062f194"}
{"doc_id": "esur__v00000000", "chunk_id": "000004", "text": "in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not\nincluded in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted\nuse, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/\nlicenses/by/4.0/.\nRosemarie Forstner and Stephanie Nougaret contributed equally to this work.\n*Correspondence:\nGiacomo Avesani\ngiacomo.avesani@policlinicogemelli.it\nFull list of author information is available at the end of the article\n1234567890():,;\n1234567890():,;\n1234567890():,;\n1234567890():,;", "section": "S P E C I A L RE P O R T", "page_from": 1, "page_to": 1, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "8003395a10c780808f7d954ca96d99ca03e55b16491c31aa71adf2c8a4e78382"}
{"doc_id": "esur__v00000000", "chunk_id": "000005", "text": "Keywords Ovarian cancer, Tomography (x-ray computed), Magnetic resonance imaging, Photon emission computed\ntomography, Structured report\nIntroduction\nOvarian cancer (OC) is the leading cause of death from\ngynaecologic malignancies, with an observed number of\ndeaths in the EU in 2017 of 26.221 and a prediction of\n26.500 deaths in 2022 [1].\nThe ovarian, fallopian tube, and primary peritoneal cancer\nare considered a single entity (referred to as OC for sim-\nplicity) because of the similar staging, management, and\nprognosis. The International Federation of Gynaecology and\nObstetrics (FIGO) system, last revised in 2014, is mostly used\nfor staging these cancers and relies on surgical exploration to\ndetermine the stage [2]. High-grade serous carcinoma is the\nmost common histologic subtype of OC, and most patients\npresent with advanced-stage disease at diagnosis [3].\nCurrently, the mainstay of OC treatment is based on\nupfront surgery (complete cytoreduction), and a platinum-\nbased combination chemotherapy [3]. The aim of surgery is\ncomplete (or at least optimal) cytoreduction. A thorough\nstaging surgery allows for diagnosis, staging, treatment, and", "section": "Introduction", "page_from": 2, "page_to": 2, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "982a231b7347c88c52ce25b30f893eb5694e9ecd3d838bd4e27662b38e47c1c7"}
{"doc_id": "esur__v00000000", "chunk_id": "000006", "text": "based combination chemotherapy [3]. The aim of surgery is\ncomplete (or at least optimal) cytoreduction. A thorough\nstaging surgery allows for diagnosis, staging, treatment, and\nassessment of the overall prognosis [4]. The results of the\nprospective multi-centre randomised Trial of Radical\nUpfront Surgical Therapy in advanced ovarian cancer\n(TRUST) are anticipated by the end of 2024. This study is\nexpected to clarify the optimal timing of cytoreductive\nsurgery by comparing outcomes of primary cytoreductive\nsurgery followed by adjuvant chemotherapy versus neo-\nadjuvant chemotherapy followed by interval cytoreductive\nsurgery [5]. In the meantime, optimal primary treatment\nselection is best achieved through multidisciplinary colla-\nboration between gynaecologic surgical oncologists, med-\nical oncologists, pathologists, and radiologists.\nPre-operative imaging delineates disease extent and facil-\nitates multidisciplinary treatment planning. This includes\nassessing the feasibility of upfront surgery, determining the\nneed for intra-operative support from other surgical spe-\ncialties, estimating operative time, and guiding biopsies if\nupfront cytoreduction is not feasible. According to the", "section": "Introduction", "page_from": 2, "page_to": 2, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "32770b816a9e32ce983bed5b98889693115d30445cbaaad9528d3231bb093e5f"}
{"doc_id": "esur__v00000000", "chunk_id": "000007", "text": "need for intra-operative support from other surgical spe-\ncialties, estimating operative time, and guiding biopsies if\nupfront cytoreduction is not feasible. According to the\nESGO-ESMO-ESP recommendations, pre-operative ima-\nging with contrast-enhanced CT, MRI, and [18F]FDG PET-\nCT, with a structured radiological report, may be considered\nfor the initial evaluation of patients with advanced ovarian\ncarcinoma, with a level of evidence IIIA [3].\nThe European Society of Urogenital Radiology (ESUR)\npublished its guidelines for OC imaging in 2010 [6]. The\npurpose of this update is to provide radiologists with\ncomprehensive guidance on imaging techniques and\nreporting for OC patients prior to treatment and during\nfollow-up, incorporating recent advances in the ﬁeld.\nThese guidelines do not cover the assessment and\ncharacterisation of ovarian masses, which are addressed\nby other ESUR guidelines and by the Ovarian-Adnexal\nReporting And Data System (O-RADS) US and O-RADS\nMRI risk stratiﬁcation systems [7–9].\nMethods\nLiterature search and questionnaire\nThe updating process has been implemented with the\nfollowing steps:\nStep 1: After reviewing the literature, three authors (S.R.,", "section": "Introduction", "page_from": 2, "page_to": 2, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "e7da9fa3fff5c994f4bd161301104872ab63061eb2bcf1cd5402379d0aabe966"}
{"doc_id": "esur__v00000000", "chunk_id": "000008", "text": "Methods\nLiterature search and questionnaire\nThe updating process has been implemented with the\nfollowing steps:\nStep 1: After reviewing the literature, three authors (S.R.,\nS.N., R.F.) designed a questionnaire regarding imaging\ntechniques used for the pre-treatment evaluation of OC.\nStep 2: A structured questionnaire of 87 questions was\ndesigned, and the questions focused on imaging techni-\nques (CT, MRI, [18F]FDG PET-CT) used for staging and\nfollow-up in OC patients.\nStep 3: The questionnaire was administered via an\nelectronic link to all ESUR Female Pelvic Imaging working\ngroup members in November 2023.\nStep 4: All responses were collected on a dedicated\nsurvey platform, analysed by four authors (G.A., S.R., S.N.,\nR.F.), and presented during the ESUR Female Pelvic\nImaging working group at the annual European Congress\nof Radiology Meeting in March 2024.\nStep 5: To address contradictory responses provided by\nthe participants, a secondary questionnaire was sent either\nto reach a consensus or for questions raised as open\nquestions in the ﬁrst round.\nStep 6: All the answers were lastly analysed by ﬁve authors\n(G.A., S.R., C.P., S.N., R.F.). Each item was categorised as", "section": "Introduction", "page_from": 2, "page_to": 2, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "c05e637b7ddfbf2d129ac701c5200303f7709fbe911eea7a29f839e658d98712"}
{"doc_id": "esur__v00000000", "chunk_id": "000009", "text": "questions in the ﬁrst round.\nStep 6: All the answers were lastly analysed by ﬁve authors\n(G.A., S.R., C.P., S.N., R.F.). Each item was categorised as\nrecommended if there was > 80% agreement among experts\nor optional if such agreement was not reached.\nStructured report\nThe proposal of a structured report was adapted accord-\ning to the survey results. The survey included the ESUR\nlexicon [6], and during the elaboration of the paper, it was\naligned with the SAR-ESUR lexicon [10].\nPaper preparation\nThe main authors prepared a ﬁrst draft of the guidelines,\nincorporating all the relevant information raised by the\nquestionnaires, during the ECR annual and online meet-\nings. They then circulated the manuscript among all\nauthors for comments and suggestions.\nResults\nThe panel (i.e., responders to both surveys) comprised 21\nexperts in the ﬁeld of gynaecological oncology imaging\nRizzo et al. European Radiology (2025) 35:4029–4039\n4030", "section": "Introduction", "page_from": 2, "page_to": 2, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "c9ac26ca517e9e16024cfc2946df7a4149e7bcec01c3472ca53891bb9037bf3a"}
{"doc_id": "esur__v00000000", "chunk_id": "000010", "text": "from 19 institutions, including 15 European Centres\n(Austria (n = 2), France (n = 3), Germany (n = 1), Italy\n(n = 2), Portugal (n = 2), Spain (n = 1), Switzerland\n(n = 2), and UK (n = 2) and 4 institutions situated\noutside Europe, Japan (n = 1) Uruguay (n = 1) and USA\n(n = 2). The years of training ranged from 5–20 years of\nexperience after fellowship.\nRecommendations\nThe recommendations cover indications and techniques\nto use for pre-treatment evaluation and follow-up, tech-\nnical parameters, standardised reports, and future per-\nspectives. The main results for recommendations are\nsummarised in Table 1.\nDetails on CT and MRI protocols are included in the\nsupplementary materials (Supplementary Table 1).\nStructured radiological reporting\nOver 80% consensus was reached for organ-based struc-\ntured reporting. The lexicon was aligned to the SAR-\nESUR lexicon for consistency, as shown in Table 2. A\ntable highlighting the differences between the 2010 and\n2024 guidelines is included in the supplementary mate-\nrials (Supplementary Table 2). For lymph node metastases\ndeﬁnition, the 2020 guidelines [6] and the node-RADS\nwere referred to [11]. Internal mammary lymph nodes", "section": "Introduction", "page_from": 3, "page_to": 3, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "355c91621575aeaead603285bac9149667ad0b9454af2c0005ace92265987729"}
{"doc_id": "esur__v00000000", "chunk_id": "000011", "text": "rials (Supplementary Table 2). For lymph node metastases\ndeﬁnition, the 2020 guidelines [6] and the node-RADS\nwere referred to [11]. Internal mammary lymph nodes\nthat were not mentioned in the node-RADS were inclu-\nded with the cardio-phrenic and retrocrural lymph nodes\nfor size reference.\nNo consensus was reached regarding the inclusion of the\nFIGO stage nor the use of surgical scores in the imaging\nreport, such as the peritoneal cancer index [12], Fagotti\nscore [13], or others. Furthermore, no consensus was\nreached about the use of RECIST criteria in the structured\nreport, as these are mainly reserved for patients who are\nenrolled in clinical trials to monitor treatment response [14].\nSites that may preclude optimal cytoreduction\nThe criteria for sites of disease that may preclude optimal\ncytoreduction may differ between centres, depending on\nthe surgical expertise, patient’s performance status, mor-\nbidity of surgery, and intensive care facilities [15].\nThe radiological report should pay special attention to\nthese sites to provide complete, clear, and relevant\ninformation\nfor\ntreatment\ndecisions\nby\nthe\nmulti-\ndisciplinary team. The main sites that may preclude", "section": "Introduction", "page_from": 3, "page_to": 3, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "11471c9cd230175bf3d6630563bfc76df1739e77a099abbcea48638f571ffae5"}
{"doc_id": "esur__v00000000", "chunk_id": "000012", "text": "these sites to provide complete, clear, and relevant\ninformation\nfor\ntreatment\ndecisions\nby\nthe\nmulti-\ndisciplinary team. The main sites that may preclude\ncomplete optimal cytoreduction [3, 15] and require spe-\nciﬁc mention in the report are summarised in Table 3, and\nsome of them are represented in Figs. 1–5. In contrast to\nthe 2010 published guidelines, the 2 cm diameter for\ndifﬁcult-to-resect sites is no longer considered valid [6].\nFurthermore, criteria for patients who are not candidates\nfor primary surgery [15] have been included.\nDiscussion\nImaging techniques\nEvaluation at diagnosis\nThe initial approach to investigating suspected adnexal\nmasses is ultrasonography (US) which can accurately\nTable 1\nRecommendations (Agreement > 80%) for evaluation\nat diagnosis and during follow-up of OC patients\nEvaluation at diagnosis\nImaging technique\nCT\nIndication\nTo conﬁrm the presence of peritoneal disease or other\nmetastatic sites of the disease\nTo deﬁne disease extent for optimal treatment planning\nTo guide percutaneous biopsy to conﬁrm diagnosis\nProtocol\nPortal venous phasea\nNo speciﬁc preparation (no fasting, no oral contrast, no\nattention to menstrual cycle)a\nMultiSlice (at least 16)", "section": "Introduction", "page_from": 3, "page_to": 3, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "ef72a220d549cc45a17855b5db009020bd769392878dffebc8cee9c84f7a7222"}
{"doc_id": "esur__v00000000", "chunk_id": "000013", "text": "To guide percutaneous biopsy to conﬁrm diagnosis\nProtocol\nPortal venous phasea\nNo speciﬁc preparation (no fasting, no oral contrast, no\nattention to menstrual cycle)a\nMultiSlice (at least 16)\n3 mm multiplanar reconstructions\nThoraxa, abdomen and pelvic\nMRI of the\nAbdomen and\npelvis\nIndication\nWhen CT with contrast medium is not feasible\nFurther assessment of potential surgically critical disease\nsites\nPregnant patients\nEvaluate the extent of serosal and mesenteric\ninvolvement\nProtocol\nAbdomen and pelvis\nSpasmolytic agenta\nContrast mediuma (optional pineapple juice per os)\nT2w, T1w, DWIa, contrast-enhanced T1w\n[18F]FDG PET-CT\nIndication\nSuspected stage IVB Equivocal lymph nodes\nProtocol\n18F Fluorodeoxyglucose-low-dose CT (or contrast-\nenhanced CT if not performed as a separate exam)\nEvaluation during Follow-up\nImaging technique\nCT\nIndication\nAfter the end of adjuvant treatment and during\nmaintenance therapy\nBefore interval debulking surgery (IDS)\nProtocol\nSimilar to staging\n[18F]FDG PET-CT\nIndication\nIf there is high suspicion but no disease on CT When\nsecondary cytoreduction is considereda\nProtocol\n[18F]FDG PET-CT (or contrast-enhanced CT if not\nperformed as a separate exam)", "section": "Introduction", "page_from": 3, "page_to": 3, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "b7516e9977ca7dec2d4d736d0a9e52eea105b706e7e2b267aeb7cb1d1ae93be6"}
{"doc_id": "esur__v00000000", "chunk_id": "000014", "text": "Indication\nIf there is high suspicion but no disease on CT When\nsecondary cytoreduction is considereda\nProtocol\n[18F]FDG PET-CT (or contrast-enhanced CT if not\nperformed as a separate exam)\na new compared to prior guidelines [6]\nRizzo et al. European Radiology (2025) 35:4029–4039\n4031", "section": "Introduction", "page_from": 3, "page_to": 3, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "f326e4e93a6c32555d3eb4c7c0b6868d0eccf05e17c0825747ef08f299af2a77"}
{"doc_id": "esur__v00000000", "chunk_id": "000015", "text": "Table 2\nRadiological report according to anatomical sites (chest, abdomen, and pelvis), with description and explanation of site\nimportance\nAnatomical sites\nDescription\nWhy\nChest\nPulmonary nodules\n– Metastases\n– Non-oncological ﬁndings: infectious/inﬂammatory\nabnormalities, interstitial/ﬁbrotic changes\n– FIGO STAGE IVB, thoracic surgeon evaluation\n– Pulmonary or infectious disease specialist evaluation\nThoracic lymphadenopathy (follow\nthe Node-RADS criteria [11])\n– Supraclavicular, mediastinal, hilar, axillary (short-axis\ndiameter ≥10 mm) Internal mammary, cardio-phrenic,\nretrocrural lymph nodes (short axis ≥5 mm\n– FIGO STAGE IVB, may need a thoracic surgeon\nevaluation\nPleural metastases\n– Yes/no\n– FIGO STAGE IVB, thoracic surgeon evaluation\nPleural effusion\n– Yes/No (if yes, small/medium/large volume, subjectively\nassessed [10])\n– FIGO STAGE IVA Drainage can be neededCytology may\nbe warranted\nOther thoracic ﬁndings\n– Non-oncological ﬁndings: cardio-vascular abnormalities,\nother anatomical variants\nAbdomen and pelvis\nLiver\n– Perihepatic implants\n– Subdiaphragmatic implants\n– Hepatic parenchyma: metastasis\n– Porta hepatis\n– FIGO STAGE III C, potentially resectable disease; describe", "section": "Table 2", "page_from": 4, "page_to": 4, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "acdfd47afe69e672de8ba8330048ffec6a513c1e1915bffc9e037386504f9310"}
{"doc_id": "esur__v00000000", "chunk_id": "000016", "text": "Abdomen and pelvis\nLiver\n– Perihepatic implants\n– Subdiaphragmatic implants\n– Hepatic parenchyma: metastasis\n– Porta hepatis\n– FIGO STAGE III C, potentially resectable disease; describe\nif deep extension into the parechyme, because hepato-\nbiliary surgeon evaluation for hepatic wedge resection\ncan be required\n– FIGO STAGE IVB; if metastasis(es) are central or\nmultisegmental in the parenchyma, they are\nconsidered difﬁcult to resect\n– Can be difﬁcult to resect\nSpleen\n– Perisplenic implants\n– Splenic parenchyma metastasis\n– FIGO STAGE III C, usually resectable disease, but better\nto plan splenectomy in advance to administer\nimmunisations\nPancreas\n– Inﬁltration of any part of the pancreas\n– May preclude optimal cytoreduction\n– Maybe resected together with the spleen\nDiaphragm\n– Right/Left/Bilateral\n– May need thoracic surgical evaluation. Diaphragmatic\nsurface along the bare area of the liver may be difﬁcult\nto visualise, and the surgeon may need more time to\nexplore these regions to achieve complete\ncytoreduction\nPeritoneal carcinomatosis outside the\npelvis\n– paracolic gutters, gastro-colic ligament, gastro-splenic\nligament, lesser omentum, lesser sac", "section": "Table 2", "page_from": 4, "page_to": 4, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "a1280ee13689b9bfbf55af3b8084663be16e559de4bf48713626bed27a4254a5"}
{"doc_id": "esur__v00000000", "chunk_id": "000017", "text": "explore these regions to achieve complete\ncytoreduction\nPeritoneal carcinomatosis outside the\npelvis\n– paracolic gutters, gastro-colic ligament, gastro-splenic\nligament, lesser omentum, lesser sac\n– May preclude optimal cytoreduction, according to the\ngynaecologist experience, and hepato-biliary surgeon\nevaluation may be required\nMesentery\n– Root of mesentery involvement\n– Pattern: nodular (mention lesion size) or inﬁltrative\n(retractile)\n– Usually preclude optimal cytoreduction\n– May preclude optimal cytoreduction\nGreater omentum\n– Thickness measurement\n– pattern (reticulonodular, nodular, or omental cake)\n– Possible bowel inﬁltration\n– Helpful for the surgical planning\nPeritoneal carcinomatosis in the\npelvis\n– Paravesical spaces, rectum, pelvic sidewall, pouch of\nDouglas\n– Helpful for the surgical planning\nAbdominal wall\n– Depth of the extension\n– May preclude optimal cytoreduction\nBowel/stomach invasion\n– Involvement and number of the implants\n– May preclude optimal cytoreduction; diffuse\ncarcinomatosis of the bowel involving more than 3\ncolon segments or such large small bowel parts that\nresection would lead to a short bowel syndrome\n(remaining bowel < 1.5 m),", "section": "Table 2", "page_from": 4, "page_to": 4, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "df4827241f881f61312a44db7c3af02f1fbae0661c4a1f4d296fbb35e914560e"}
{"doc_id": "esur__v00000000", "chunk_id": "000018", "text": "carcinomatosis of the bowel involving more than 3\ncolon segments or such large small bowel parts that\nresection would lead to a short bowel syndrome\n(remaining bowel < 1.5 m),\nRizzo et al. European Radiology (2025) 35:4029–4039\n4032", "section": "Table 2", "page_from": 4, "page_to": 4, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "2b3ebce843d742e7b9d6469de14ce820adf2e5fc3d8a20fad43c93845790d4a9"}
{"doc_id": "esur__v00000000", "chunk_id": "000019", "text": "characterise approximately 80% of adnexal masses [16]. In\ncases where the US is inconclusive, MRI serves as the\nsecond-line technique for lesion characterisation, with\nO-RADS evaluation being recommended [8, 17].\nWhen malignancy is suspected, the use of contrast-\nenhanced CT is advised for the evaluation of disease\nextent. CT is the imaging modality of choice because of its\nwidespread\navailability,\nrapid\nimaging\ntime,\ncost-\nTable 2 continued\nAnatomical sites\nDescription\nWhy\nLymphadenopathy (follow the Node-\nRADS criteria [11])\nAbdominal lymph nodes (short axis ≥10 mm)\n– Retroperitoneal above the renal arteries (supra-renal para-\naortic, inter-cavo-aortic)\n– Retroperitoneal below renal arteries (infra-renal para-aortic,\ninter-cavo-aortic)\n– Mesenteric\n– Pelvic (common iliac, external iliac, internal iliac,\nobturatory, parametrial, mesorectal)\nInguinal lymph nodes (short axis ≥15 mm)\n– Upper abdominal lymph nodes may preclude optimal\ncytoreduction, if the vessels are inﬁltrated; vascular\nsurgeon evaluation can be requested\n– FIGO STAGE IVB, but they may be removed surgically, if\nappropriate\nAscites\n– Yes/No (if yes, small/medium/large volume subjectively\nassessed [10]))", "section": "Table 2", "page_from": 5, "page_to": 5, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "4e47bc03e5397510a8d87f6da4f4cf08eab27dc765920cd30ba98c83354ca50c"}
{"doc_id": "esur__v00000000", "chunk_id": "000020", "text": "surgeon evaluation can be requested\n– FIGO STAGE IVB, but they may be removed surgically, if\nappropriate\nAscites\n– Yes/No (if yes, small/medium/large volume subjectively\nassessed [10]))\n– Drainage may be needed for large volume\n– Cytology may be warranted\nAdnexal lesion\nDescription\n– Unilateral, bilateral, cystic, solid tissue, and other solid\ncomponents, if evident. Statement of whether the mass\ndemonstrates features of malignancy\n– Largest dimension\n– In adjacent organ inﬁltration is present\n– Helpful for the surgical planning\n– Useful for surgical planning\n– Useful for surgical planning\nEvidence of complications\n– Bowel obstruction\n– Hydronephrosis\n– Venous obstruction/thrombosis\n– Pulmonary embolism\n– May need emergency surgery, urologist consultation\n– May need to go for neo-adjuvant chemotherapy\ninstead of primary surgery\n– It needs speciﬁc urgent treatment\nAnatomical variants\n– Abdominal vessels\n– Urinary tracts\n– Other visceral abnormalities\n– Helpful for surgical planning to avoid damage\nOthers\n– Exclude the presence of other malignancies that may be\nassociated with peritoneal carcinomatosis, such as gastro-\nintestinal cancer or pancreatic cancer", "section": "Table 2", "page_from": 5, "page_to": 5, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "86af2e864ebc8c717beae1cdbda0a2ac6bd26951eeb35dcbcd302ce983c7be62"}
{"doc_id": "esur__v00000000", "chunk_id": "000021", "text": "Others\n– Exclude the presence of other malignancies that may be\nassociated with peritoneal carcinomatosis, such as gastro-\nintestinal cancer or pancreatic cancer\n– The treatment planning is different\nTable 3\nSites of disease that may preclude optimal cytoreduction and require speciﬁc mention in the report\nThoracic lesions\nPulmonary nodules\nThoracic lymphadenopathy (except for cardio-phrenic)\nPleural metastases\nAbdominopelvic lesions\nHepatic parenchyma (central or multisegmental)\nPancreas (head or body)\nLesser sac\nMesentery (diffuse, multifocal, or mesenteric root involvement)\nAbdominal wall\nBowel/stomach involvement (involving such large parts that resection would lead to a short bowel syndrome if the remaining bowel < 1.5 m)\nUpper abdominal lymphadenopathy (above the renal arteries)\nInguinal lymph nodes\nOther visceral lesions\nRizzo et al. European Radiology (2025) 35:4029–4039\n4033", "section": "Table 2", "page_from": 5, "page_to": 5, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "bcfd7124ddb425f98ee9340f273ecdf9cb77c808bc21b717db9ec421d8043864"}
{"doc_id": "esur__v00000000", "chunk_id": "000022", "text": "effectiveness, and utility in the follow-up, providing con-\nsistent and reproducible results [18]. The portal venous\nphase is the recommended contrast phase for this pur-\npose. To ensure high accuracy, CT should be performed\nusing a multislice CT scanner, and multiplanar recon-\nstructions should be reviewed to increase conﬁdence in\ninterpreting the scans [19].\nA signiﬁcant update to the guidelines is the recom-\nmendation to include chest CT for complete staging. It\nprovides\ncrucial\ninformation\nabout\npotential\nextra-\nabdominal disease, impacting treatment planning. Nota-\nbly, the CT protocol does not require speciﬁc preparation,\nsuch as fasting, oral contrast administration, or spasmo-\nlytic drugs [20]. Indeed, none of these preparations\nreached consensus.\nThe present updated ESUR guidelines recommend a CT\nscan as the initial evaluation for patients with advanced\nOC before debulking surgery, with the option to choose a\ncombination of chest CT and MRI abdomen and pelvis as\na valid alternative when iodine contrast media cannot be\nadministered and in pregnant women. A speciﬁc question\nto the experts’ panel on pre-operative evaluation of young", "section": "Table 2", "page_from": 6, "page_to": 6, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "fcd902289b897cf747bcd809f081fe4e07ea30a621f683a4777e3002c3e64a99"}
{"doc_id": "esur__v00000000", "chunk_id": "000023", "text": "a valid alternative when iodine contrast media cannot be\nadministered and in pregnant women. A speciﬁc question\nto the experts’ panel on pre-operative evaluation of young\npatients did not reach consensus about the imaging\ntechnique (i.e., not performing CT and only MRI) to use,\ntherefore it can be adapted to the single centre’s pre-\nference and experience [21].\nWhen used for pre-treatment evaluation, abdominal\nMRI should include T1- and T2-weighted imaging and\ndiffusion-weighted imaging (DWI) of the abdomen and\npelvis, with the administration of a spasmolytic drug, to\nminimise motion artefacts. Gadolinium-based contrast\nagents can be used to complete evaluation. The use of\npineapple juice has been proposed as an adjunct to\nminimise the hyper T2 effect of the bowel lumen (Sup-\nplementary Table 1). MRI protocol may be adjusted based\non the indication of the exam.\nWhole-body (WB)-MRI may be considered for a site-\nbased analysis of sub-centimetre lesions, where DWI\nFig. 1 Sites of disease that may preclude optimal cytoreduction include:\nhepatic parenchyma metastases (red); metastases in the porta hepatis\n(pink); metastases in the lesser sac (blue) and lesser omentum (violet);", "section": "Table 2", "page_from": 6, "page_to": 6, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "3220473ac8f9f4806a47cf4d36b74d9ef1eea5f529961dfcda87ff20cf44a415"}
{"doc_id": "esur__v00000000", "chunk_id": "000024", "text": "hepatic parenchyma metastases (red); metastases in the porta hepatis\n(pink); metastases in the lesser sac (blue) and lesser omentum (violet);\nmetastases in the head of the pancreas (orange) and in the gastric wall\n(purple)\nFig. 2 Thoracic sites of disease that may preclude optimal debulking include right internal mammary lymphadenopathy (white arrow in (a); pleural\nlesions (white arrowhead in (b)); lung metastases (black arrow in (c))\nRizzo et al. European Radiology (2025) 35:4029–4039\n4034", "section": "Table 2", "page_from": 6, "page_to": 6, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "5d576c4561e2655da8af88ae70584db2c3f6c33210d45991ec4f58e58cb77e84"}
{"doc_id": "esur__v00000000", "chunk_id": "000025", "text": "Fig. 3 Axial (a) and coronal (b) CT images show inﬁltration of the lesser sac (white arrow) and of the hepatic hilum (black arrowhead)\nFig. 4 Small bowel mesentery Inﬁltration: axial (a, b) and sagittal (c) CT images of a diffuse deep inﬁltration (white arrows)\nFig. 5 Abdominal MR images showing inﬁltration of the small bowel mesentery as hypointense thickening of the mesenteric surface on T2w images (a)\nand as an area with restricted diffusion on DWI MRI images (b); subtle inﬁltration of the hepatic hilum on axial T2-weighted (c) and high b-Value DWI MRI\nimages (d). MRI can be used as a complement to CT as a problem-solving tool, like evaluating the extent of serosal and mesenteric involvement or bowel\ninvolvement\nRizzo et al. European Radiology (2025) 35:4029–4039\n4035", "section": "Table 2", "page_from": 7, "page_to": 7, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "1b4b5b263392e093ac3cb12d860e1284529e8846229c44c9a6aaa6dd5daa9f18"}
{"doc_id": "esur__v00000000", "chunk_id": "000026", "text": "sequences, combined with morphological sequences, may\noutperform CT [22] and [18F]FDG PET-CT [23] to detect\nchallenging to resect sites, such as serosal and mesenteric\ninvolvement. However, this technique is less available,\nmore expensive, longer, and thus harder for patients.\nFurthermore, it requires a lot more expertise to perform\nand interpret appropriately. Therefore, more studies\nshould be performed to conﬁrm WB-MRI superiority\ncompared to the other techniques, before its imple-\nmentation in the clinical routine, especially over abdom-\ninal and pelvic MRI.\n[18F]FDG PET-CT has a limited role in the initial eva-\nluation of patients with OC and is not recommended as a\nﬁrst-line imaging technique. Indeed, [18F]FDG PET-CT\ncannot differentiate reliably between borderline and\nbenign tumours; it may fail to detect clear cell and\nmucinous invasive subtypes due to low FDG uptake as\nwell as give false positive results in the presence\nof endometriosis and hydrosalpinxes [24, 25]. Although\n[18F]FDG PET-CT may be as accurate as CT in predicting\nthe presence of chest metastasis, it fails to detect small\nperitoneal metastases [26], therefore its role in initial", "section": "Table 2", "page_from": 8, "page_to": 8, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "351b433a63eb8a9cd51f584f54d69b0fb6c04ca191e5674930c641287da21551"}
{"doc_id": "esur__v00000000", "chunk_id": "000027", "text": "[18F]FDG PET-CT may be as accurate as CT in predicting\nthe presence of chest metastasis, it fails to detect small\nperitoneal metastases [26], therefore its role in initial\nevaluation is limited to the evaluation or conﬁrmation of\npossible extraperitoneal spread of disease. On the other\nhand, [18F]FDG PET-CT may be valuable in evaluating\nambiguous extra-abdominal ﬁndings, such as extra-\nabdominal lymph nodes [27], that could inﬂuence treat-\nment decisions.\nFollow-up and recurrence\nPost-treatment surveillance of OC typically involves a\ncombination of clinical examination, routine CA-125\nblood tests, and periodic imaging. There is currently no\nstandardised clinical recommendation for imaging fre-\nquency, and radiological imaging may be indicated\naccording to histology of the tumour, symptoms, clinical\nexamination or rising of CA-125 level, or other markers\n[15]. The crucial issue is to perform the same imaging\nmodality each time to be able to compare. Still, CT scans\nare commonly performed at intervals of three to six\nmonths or when recurrence is suspected based on clinical\nor laboratory ﬁndings [15].\nIndeed our survey indicated that CT remains the pri-", "section": "Table 2", "page_from": 8, "page_to": 8, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "471012c67fce8b60316a34e69dffcce7e8fff7067fac357895c68535aac50a9c"}
{"doc_id": "esur__v00000000", "chunk_id": "000028", "text": "are commonly performed at intervals of three to six\nmonths or when recurrence is suspected based on clinical\nor laboratory ﬁndings [15].\nIndeed our survey indicated that CT remains the pri-\nmary imaging modality for follow-up and assessment of\ntreatment response. The CT protocol for follow-up is the\nsame as for evaluation at diagnosis.\nTo date, not enough studies have evaluated the role of\nMRI in terms of follow up and recurrence, therefore these\nguidelines cannot give any recommendation about its use\nduring follow-up. However, the use of MRI for follow-up\ncould be discussed in multidisciplinary teams for young\npatients to save radiation exposure.\n[18F]FDG PET-CT may be beneﬁcial in cases where CA-\n125 levels are elevated, but CT is negative. [18F]FDG PET-\nCT may also help detect persistent disease and notice\ndistant sites when planning a secondary cytoreductive\nsurgery [28]. Indeed, results of a retrospective multi-\ncentric trial demonstrated improved progression-free\nsurvival and a longer time to ﬁrst subsequent therapy in\nOC patients that, at ﬁrst recurrence, underwent secondary\ncytoreductive surgery, with no residual disease [29].\nStructured report", "section": "Table 2", "page_from": 8, "page_to": 8, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "244f0d9b467e54354b195b74c78c229427240887173b1c7e77b6226d2a8f64c2"}
{"doc_id": "esur__v00000000", "chunk_id": "000029", "text": "survival and a longer time to ﬁrst subsequent therapy in\nOC patients that, at ﬁrst recurrence, underwent secondary\ncytoreductive surgery, with no residual disease [29].\nStructured report\nThe use of a structured report for the pre-treatment evalua-\ntion of OC using CT or MRI is recommended [10, 30, 31],\nsince it enhances uniformity in disease reporting and\nimproves communication between radiologists and clinicians,\npotentially leading to better treatment choice and surgical\nplanning and hence optimal patient care. This is particularly\nrelevant as not all lesions are clearly visible at laparoscopy\n(behind the upper part of the liver, for example) and need to\nbe removed if a primary surgery is decided.\nA structured radiological report should provide com-\nprehensive information about the primary tumour and its\ndissemination in the peritoneal cavity, the presence of\nlymph node enlargement, parenchymal involvement of\nthoracic,\nabdominal,\nand\npelvic\norgans,\nand\nextra-\nabdominal tumour spreading. A study including 205\nreports showed that the implementation of a synoptic\nreport at the initial CT evaluation of patients with\nadvanced OC, improved the overall documentation rate of", "section": "Table 2", "page_from": 8, "page_to": 8, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "a2624553407b425bda93b9f649463d59bf36ecda3939f856e649fb8df3cefb79"}
{"doc_id": "esur__v00000000", "chunk_id": "000030", "text": "reports showed that the implementation of a synoptic\nreport at the initial CT evaluation of patients with\nadvanced OC, improved the overall documentation rate of\ndisease extent from 39% for simple structured reports to\n99% for synoptic reports and unresectable or challenging-\nto-resect sites from 37% to 100%, respectively [32].\nThe expert panel advises an organ-based disease\ndescription with detailed mapping of the peritoneal sites\nin the radiological report. The recommended structured\nreport essential items are summarised in Table 2.\nCompared to the 2010 guidelines [6], a description of\nvascular variants (such as the position of the left renal vein\ncompared to the aorta) is now recommended to help\nsurgeons\navoid\ncomplications\nduring\nlymph\nnode\ndissection.\nThe deﬁnition of lymph nodes as metastatic has reached\nconsensus, indicating positive lymph nodes in general\nwith a short axis ≥10 mm, except for cardio-phrenic,\nretrocrural, and internal mammary lymph nodes, con-\nsidered positive with a short axis ≥5 mm, and of inguinal\nlymph nodes considered positive with a short axis\n≥15 mm [11]. Although different short axis sizes have\nbeen described in multiple papers [10, 33], in these", "section": "Table 2", "page_from": 8, "page_to": 8, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "49e4fc3bf3b3627bd666ee65722e9ddb1f00423add1d0cedf4a5c0973f5237ba"}
{"doc_id": "esur__v00000000", "chunk_id": "000031", "text": "lymph nodes considered positive with a short axis\n≥15 mm [11]. Although different short axis sizes have\nbeen described in multiple papers [10, 33], in these\nguidelines, intended also for general practice radiologists,\nthe expert panel decided to keep it simple and to adopt\nthe node-RADS size criteria, that align with the 2010\nguidelines\n[6,\n11].\nHowever,\na\ndiscussion\nin\nthe\nRizzo et al. European Radiology (2025) 35:4029–4039\n4036", "section": "Table 2", "page_from": 8, "page_to": 8, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "41bd306da076325a41191e5514a7c97df4868e67fe79bb5ca34d70339d7626f2"}
{"doc_id": "esur__v00000000", "chunk_id": "000032", "text": "multidisciplinary meeting may be helpful about the sig-\nniﬁcance\nof\nslightly\nenlarged\nextra-abdominal\nlymph nodes.\nThe inclusion of the FIGO/TNM classiﬁcation, perito-\nneal cancer index, or other scores did not reach > 80%\nagreement. The gynaecological surgeons make the deci-\nsion on how far a cytoreductive surgery can go, con-\nsidering the patient’s performance status and disease-\nrelated factors, together with imaging evaluation of the\ndisease extension. For this reason, the imaging criteria for\nsites that may preclude optimal cytoreduction in OC\nshould always be discussed and approved in a multi-\ndisciplinary meeting [34]. There are also some locations\nindicating that patients may not be candidates for primary\nsurgery, and these should be described in the report and\npossibly discussed during a multidisciplinary meeting.\nCompared to the 2010 guidelines, the cut-off of 2 cm for the\nperitoneal supra-mesocolic and small bowel peritoneal\nmetastases did not reach consensus and have been removed.\nPotential implementations in the future\nAlthough not included in the recommendations of these\nguidelines, aimed at a practical approach, technological", "section": "Table 2", "page_from": 9, "page_to": 9, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "f9002b9432e6df7492d6bec3d65b966e471804d5a52430b66a766200ae55f424"}
{"doc_id": "esur__v00000000", "chunk_id": "000033", "text": "Potential implementations in the future\nAlthough not included in the recommendations of these\nguidelines, aimed at a practical approach, technological\nand computational developments that are underway are\nhere mentioned, as they may have already a role in few\ncentres or may be more spread out in the future.\nPET-MRI\nCombined PET-MRI has been available for clinical use\nsince 2010; however, the number of installed PET-MRI\nsystems is still small compared to clinical [18F]FDG\nPET-CT systems [24]. Today, PET-MRI is primarily\nperformed for oncological indications. Still, its adoption\nhas been challenged by the lack of protocol, workﬂow\nstandardisation [24], and reimbursement, which is often\nnon-existent or variable between countries [35]. Given\nthe challenges of standardisation and harmonisation of\nMRI data acquisition, a clinical trial comparing this\nimaging modality to the existing ones is considered\ndifﬁcult to achieve. For this reason, a PET-MRI registry\nfor pooling data acquired at multiple centres was cre-\nated. In the speciﬁc clinical setting of OC, [18F]FDG\nPET-CT, and PET-MRI demonstrated accuracy rates of\n71% and 92.5% in the peritoneal staging and character-", "section": "Table 2", "page_from": 9, "page_to": 9, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "1bad7fc9ec6fe40391c011372e350a8fd3927f2dc658a5ef48582f4a769c0681"}
{"doc_id": "esur__v00000000", "chunk_id": "000034", "text": "ated. In the speciﬁc clinical setting of OC, [18F]FDG\nPET-CT, and PET-MRI demonstrated accuracy rates of\n71% and 92.5% in the peritoneal staging and character-\nisation of suspected OC [36]. In a group of 34 patients,\nPET-MRI was more accurate than DW-MRI (p = 0.001)\nwhen evaluating patients at primary diagnosis, although\nno difference was noted in patients treated with che-\nmotherapy. In the small bowel regions, there was a\ntendency towards higher sensitivity but lower speciﬁcity\nof PET-MRI compared to DW-MRI. Few published\nstudies suggest the high diagnostic potential of PET-\nMRI for the assessment of the recurrence of female\npelvic malignancies and higher diagnostic conﬁdence in\ndiscrimination between benign and malignant lesions\ncompared to [18F]FDG PET-CT [37]. In the future,\nfurther studies are suggested, possibly randomised and\nprospective, to assess the added value of the PET-MRI\nimaging modality.\nArtiﬁcial intelligence/radiomics\nArtiﬁcial intelligence (AI), a branch of computer science,\nrefers to the ability of computer systems to learn from\ninput data. AI is playing an essential role in many different\nareas of imaging. In recent years, AI-based multi-omics", "section": "Table 2", "page_from": 9, "page_to": 9, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "638bebedad2f0b2a9b3b2cef7362bdcafec32f205afb706d4bedc0652551677a"}
{"doc_id": "esur__v00000000", "chunk_id": "000035", "text": "refers to the ability of computer systems to learn from\ninput data. AI is playing an essential role in many different\nareas of imaging. In recent years, AI-based multi-omics\nresearch has been widely conducted with a focus on OC\n[38]. Radiomics is part of the AI non-invasive approaches\nthat aim to create prediction models by extracting\nquantitative features from medical images through spe-\nciﬁc steps, such as image acquisition, segmentation, fea-\nture extraction, and model construction [39]. Although\nmany issues need to be addressed, primarily related to the\nquality of the studies and the possibility of routine clinical\napplications\nof\npredictive\nradiomic\nsignatures\n[40],\nradiomics raises particular hope in OC to capture the\nwhole disease heterogeneity better and offer a new tool to\npredict tumour aggressiveness, response to therapy and\nsurvival [41–45]. Furthermore, studies addressing the\nadvances in research on molecular targeted therapies and\nhow they may be reﬂected by imaging would be of great\nhelp in the future. The future of radiomics clinical\napplication may rely on large multicentric studies, always\nincluding appropriate validation cohorts to ensure the", "section": "Table 2", "page_from": 9, "page_to": 9, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "56931504eca3831b36a10b17c0f9df6f6881a12bd048bee256b1764e96865428"}
{"doc_id": "esur__v00000000", "chunk_id": "000036", "text": "help in the future. The future of radiomics clinical\napplication may rely on large multicentric studies, always\nincluding appropriate validation cohorts to ensure the\nreproducibility of models and performed according to\nhigh-quality standards [46].\nIn conclusion, the ESUR Female Imaging working group\nhas updated the guidelines for imaging of patients with\nOC, recommending contrast-enhanced chest, abdominal,\nand pelvic CT for pre-treatment evaluation and follow-up.\nA structured report, including all sites of disease reported\naccording to the SAR-ESUR lexicon, has been introduced;\nthe sites of disease that may preclude an optimal cytor-\neduction are highlighted to pay special attention to them\nwhen reporting the CT exam and presenting the results to\nthe multidisciplinary meetings, where the decision on\nprimary debulking or interval debulking surgery should be\nundertaken.\nAbbreviations\nESUR\nEuropean Society of Urogenital Radiology\nFIGO\nInternational Federation of Gynaecology and Obstetrics\nOC\nOvarian cancer\nO-RADS\nOvarian-Adnexal Reporting and Data System\nSAR\nSociety of American Radiology\nTRUST\nTrial\nof\nRadical\nUpfront\nSurgical\nTherapy\nin\nadvanced\novarian cancer\nUS\nUltrasonography\nWB", "section": "Table 2", "page_from": 9, "page_to": 9, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "b97bf7b99a910d999568c3b6fdd7d5b300d4a9ab5808cb735a65ed4ebd9a1926"}
{"doc_id": "esur__v00000000", "chunk_id": "000037", "text": "OC\nOvarian cancer\nO-RADS\nOvarian-Adnexal Reporting and Data System\nSAR\nSociety of American Radiology\nTRUST\nTrial\nof\nRadical\nUpfront\nSurgical\nTherapy\nin\nadvanced\novarian cancer\nUS\nUltrasonography\nWB\nWhole-body\nRizzo et al. European Radiology (2025) 35:4029–4039\n4037", "section": "Table 2", "page_from": 9, "page_to": 9, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "0d61ea2c0c7df857ba32a7be2a02069f0e5b1aa19451526de86ee220e37cda38"}
{"doc_id": "esur__v00000000", "chunk_id": "000038", "text": "Supplementary information\nThe online version contains supplementary material available at https://doi.\norg/10.1007/s00330-024-11300-7.\nAcknowledgements\nThanks to Keydiag.org for their assistance with Fig. 1.\nFunding\nThe authors state that this work has not received any funding.\nCompliance with ethical standards\nGuarantor\nThe scientiﬁc guarantor of this publication is Stefania Rizzo.\nConﬂict of interest\nThe authors of this manuscript declare no relationships with any companies,\nwhose products or services may be related to the subject matter of the article.\nStatistics and biometry\nNo complex statistical methods were necessary for this paper.\nInformed consent\nWritten informed consent was not required.\nEthical approval\nInstitutional Review Board approval was not required.\nStudy subjects or cohorts overlap\nNot applicable\nMethodology\n●Guidelines\nAuthor details\n1Imaging Institute of Southern Switzerland (IIMSI), Ente Ospedaliero Cantonale\n(EOC), via Tesserete 46, 6900 Lugano, Switzerland. 2Faculty of Biomedical\nSciences, Università della Svizzera italiana (USI), via G. Bufﬁ13, 6900 Lugano,\nSwitzerland. 3Department of Imaging and Radiation Oncology, Fondazione", "section": "Supplementary information", "page_from": 10, "page_to": 10, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "56d646d3ecfa011d3fb872253ecd1041a19229c500a571b8ee72c994c15e2eb6"}
{"doc_id": "esur__v00000000", "chunk_id": "000039", "text": "Sciences, Università della Svizzera italiana (USI), via G. Bufﬁ13, 6900 Lugano,\nSwitzerland. 3Department of Imaging and Radiation Oncology, Fondazione\nPoliclinico Universitario A. Gemelli IRCCS, Rome, Italy. 4Department of\nRadiological, Oncological and Pathological Sciences, Sapienza University of\nRome, Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy.\n5Department of Radiology, Memorial Sloan Kettering Cancer Center, New York,\nNY, USA. 6Department of Radiology, Mayo Clinic, Rochester, MN, USA.\n7Department of Radiology, Imperial College Healthcare NHS Trust, London, UK.\n8Department of Surgery and Cancer, Faculty of Medicine, Imperial College\nLondon, London, UK. 9Radiology Imaging and Interventional Radiology\nSpecialized Department (IRIS), Tenon Hospital, Public Hospital of Paris, Paris,\nFrance. 10Department of Radiology, Instituto Português de Oncologia de\nLisboa Francisco Gentil, Lisbon, Portugal. 11Department of Radiology,\nUniversity Hospital of Salzburg, PMU, Salzburg, Austria. 12Department of\nRadiology, Montpellier Research Center Institute, PINKCC Laboratory,\nMontpellier, France.\nReceived: 7 September 2024 Revised: 26 October 2024 Accepted: 17\nNovember 2024", "section": "Supplementary information", "page_from": 10, "page_to": 10, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "1ae856b641f52f1155701d8ac4a41566cd08d6e374f7100cce35962e67108197"}
{"doc_id": "esur__v00000000", "chunk_id": "000040", "text": "Radiology, Montpellier Research Center Institute, PINKCC Laboratory,\nMontpellier, France.\nReceived: 7 September 2024 Revised: 26 October 2024 Accepted: 17\nNovember 2024\nPublished online: 11 January 2025", "section": "Supplementary information", "page_from": 10, "page_to": 10, "display_name": "ESUR", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "5dbef02b20cc204b855d0d1daa4efae8b6aa6ec53f7ccbba9f55731a1ded6f85"}
